Valeritas Holdings (VLRX) Stock: Climbing On Clinical Data

Valeritas Holdings Inc (NASDAQ: VLRX) is climbing in the market today, and for good reason. The company announced positive clinical outcomes of its V-Go device, exciting investors and pushing the stock on a run up. Today, we’ll talk about:

  • The data;
  • what we’re seeing from VLRX stock as a result; and
  • what we’ll be watching for ahead. 

VLRX Heads Up On Data

As mentioned above, Valeritas Holdings is having a great day in the market today after announcing positive clinical data. In a press release, the company said that it achieved positive clinical outcomes for its V-Go Wearable Insulin Delivery Device when compared to insulin pen devices. 

The study specifically focused on the treatment of patients with type 2 diabetes that have been prescribed basal-bolus insulin therapy. In the release, VLRX said that the data from the study was presented at the 12th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD 2019). 

The study was a retrospective one that used electronic medical records of 148 patients across nine diabetes centers located within the United States. Patients that were using a pen device prior to the use of V-Go were included in the evaluation. 

At months three and seven, patients using V-Go experienced statistically significant reduction in both A1c levels and the daily dose of insulin required to manage the condition. 

In a statement, John Timberlake, President and CEO at VLRX, had the following to offer:

We are excited to share these positive data from our clinical study at ATTD 2019. We believe the results of this study further support when basal-bolus insulin therapy is needed, the use of V-Go Wearable Insulin Delivery device can offer significant clinical benefit.

What We’re Seeing From The Stock 

One of the first lessons that we learn when we start to work in the market is that the news leads to moves. In the case of Valeritas, the news proved to be overwhelmingly positive. After all, the company’s V-Go showed not only to be superior in the reduction of A1c, but can also reduce the amount of insulin necessary to treat type 2 diabetes patients. 

Considiering the data, it’s not surprising to see that excited investors are pushing the stock for the top. After all, the strong data means that the company now has more ammunition in the commercialization of the V-Go device. 

As is just about always the case, our partners at Trade Ideas were the first to alert us to the gains. Currently (9:47), VLRX is trading at $0.44 per share aafter a gain of $0.041 per share or 10.28% thus far today. 

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will continue to keep a close eye on VLRX. In particular, we’re interested in following the continued effort to bring the V-Go device to patients in need and how the data announced today will help in that effort. Nonetheless, we’ll continue to follow the story closely and bring the news to you as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!
* indicates required

Leave a Comment